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Abstract
Low doses of anticancer drugs have been shown to enhance antitumor immune response and increase the efficacy of
immunotherapy. The molecular basis for such effects remains elusive, although selective depletion of T regulatory cells has
been demonstrated. In the current studies, we demonstrate that topotecan (TPT), a topoisomerase I-targeting drug with a
well-defined mechanism of action, stimulates major histocompatibility complex class I (MHC I) expression in breast cancer
cells through elevated expression/secretion of interferon-b (IFN-b) and activation of type I IFN signaling. First, we show that
TPT treatment elevates the expression of both total and cell-surface MHC I in breast cancer cells. Second, conditioned media
from TPT-treated breast cancer ZR-75-1 cells induce elevated expression of cell-surface MHC I in drug-naı ¨ve recipient cells,
suggesting the involvement of cytokines and/or other secreted molecules. Consistently, TPT-treated cells exhibit elevated
expression of multiple cytokines such as IFN-b, TNF-a, IL-6 and IL-8. Third, either knocking down the type I interferon
receptor subunit 1 (IFNAR1) or addition of neutralizing antibody against IFN-b results in reduced MHC I expression in TPT-
treated cells. Together, these results suggest that TPT induces increased IFN-b autocrine/paracrine signaling through type I
IFN receptor, resulting in the elevated MHC I expression in tumor cells. Studies have also demonstrated that other
chemotherapeutic agents (e.g. etoposide, cisplatin, paclitaxel and vinblastine) similarly induce increased IFN-b secretion and
elevated MHC I expression. In addition, conditioned media from c-irradiated donor cells are shown to induce IFN-b-
dependent MHC I expression in unirradiated recipient cells. In the aggregate, our results suggest that many cancer
therapeutics induce elevated tumor antigen presentation through MHC I, which could represent a common mechanism for
enhanced antitumor immune response through T cell cytotoxicity during metronomic chemotherapy, as well as increased
efficacy of combined chemo- (or radio-)/immuno-therapy.
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Introduction
Cancer vaccines hold great promise for cancer therapy due to
their highly specific, well tolerated, and long-lasting anti-tumor
effect. However, it is well known that tumors develop various
immune escape mechanisms to evade the host immune system,
which could be the major reason accounting for the failure of
immunotherapy [1].
Repeated low-dose chemotherapy (metronomic chemotherapy)
has been shown to induce antitumor immune response [2]. Studies
have also demonstrated that low doses of certain cancer
chemotherapeutics and ionizing radiation can enhance the efficacy
of immunotherapy (e.g. dendritic cell- and DNA vaccine-based
immunotherapies) [3]. For example, pretreatment with low-dose
cyclophosphamide (CTX), as a single agent or in combination
with other anticancer drugs, has been shown to enhance cytotoxic
T lymphocyte (CTL)-mediated antitumor immune response to
tumor vaccination in animal models [4,5]. In metastatic pancreatic
cancer patients receiving a cell-based cancer vaccine, low-dose
CTX administration has been shown to enhance antigen-specific
CTL cytotoxicity [6]. It appears that chemotherapy could restore
immune surveillance perhaps by breaking the tumor immune
escape mechanisms. Indeed, low-dose chemotherapeutics have
been observed to selectively deplete T regulatory cells that are
known to represent a major tumor immune escape mechanism
[7–10].
Another tumor immune escape mechanism involves blunted
antigen presentation through reduced expression of major
histocompatibility complex class I (MHC I) molecules on the
tumor cell surface [11]. Consisting of a transmembrane a chain
and b2 microglobulin (b2 m), the MHC I heterodimers present
antigens to antigen-specific CTLs, resulting in cell killing [12].
While MHC I is present on the surfaces of all normal nucleated
cells, deficiency of MHC I antigen presentation is very frequent in
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32542tumors [11]. Several studies have demonstrated low-dose chemo-
therapy can elevate antigen presentation by MHC I, which has
been suggested to be a potential mechanism for immune
sensitization of tumors [10,13,14].
Camptothecins (CPTs) such as topotecan (TPT) and irinotecan
have been used in the clinic for the treatment of ovarian, colon,
lung and other cancers (reviewed in [15]). The mechanism of
tumor cell killing by CPTs has been well advanced. In the
presence of CPTs, DNA topoisomerase I molecules are trapped on
DNA as reversible Top1-CPT-DNA ternary complexes which
arrest the advancing replication forks, resulting in S phase-specific
killing of tumor cells (reviewed in [16,17]). Because of its well
characterized mechanism of tumor cell killing, we have employed
TPT as a model to study tumor immune sensitization by cancer
therapeutics. In the current studies, we have observed that TPT, as
well as many other chemotherapeutics and ionizing radiation,
induces elevated MHC I expression in breast cancer cells through
induction of IFN-b, suggesting that elevated tumor antigen
presentation through IFN-b autocrine/paracrine signaling could
represent a common mechanism underlying tumor immune
sensitization by cancer therapeutics.
Results
TPT elevates MHC I expression in breast cancer cells
Previous studies have shown that MHC I expression was
enhanced after treatment with cisplatin, fluorouracil, SN-38 or 5-
aza-29-deoxycytidine [13,14,18]. To test whether MHC I can also
be induced by TPT, we treated breast cancer cells lines ZR-75-1,
MCF-7, T47D and MDA-MB-231 with TPT for 4 days, followed
by immunoblotting using an anti-MHC I polyclonal antibody. As
shown in Fig. 1A, TPT induced elevated expression of total
cellular MHC I in all four cell lines. We also performed a study
with different concentrations of TPT in ZR-75-1 cells. As shown in
Fig. 1B, at as low as 40 nM, TPT induced significant elevation of
cellular MHC I expression. The decrease of a-tubulin levels in
TPT-treated ZR-75-1 cells indicates cell loss/death due to the
cytotoxic activity of TPT [19]. The fold-induction of MHC I upon
normalization is about 4 at 40 nM of TPT (Fig. 1B). In a time-
course study, ZR-75-1 cells were incubated with 40 nM of TPT
for various times (0, 1, 6, and 24 hrs), followed by incubation in
drug-free medium for a combined incubation time (drug
treatment+drug-free incubation) of 4 days. As shown in Fig. 1C,
MHC I expression was elevated (,3-fold) after as short as 1 hr of
TPT treatment. In addition to measuring total cellular MHC I,
cell-surface expression of MHC I was also monitored by FACS
using the pan-MHC I monoclonal antibody W6/32. As shown in
Fig. 1D, 1 hr TPT treatment (40 nM) followed by 4-day
incubation resulted in greatly elevated surface expression of
MHC I (the mean fluorescence intensity increased from 7.16 to
13.1), suggesting elevated antigen presentation through MHC I in
TPT-treated ZR-75-1 cells.
TPT treatment of breast cancer cells increases IFN-b
secretion
Tumor cells are known to secrete various cytokines, chemo-
kines, as well as angiogenic and growth factors [20]. Chemother-
apeutics such as doxorubicin and cisplatin have been shown to
increase the secretion of cytokines such as IL-6 and IL-8, as well as
other molecules from tumor cells [21–23]. To investigate a
possible involvement of cytokines in the TPT-induced MHC I
elevation, we harvested conditioned media from TPT-treated ZR-
75-1 cells, and transferred them to drug-naı ¨ve ZR-75-1cells. As
shown in Fig. 2, conditioned media from TPT-treated cells
stimulated the expression of both total cellular (Fig. 2A, immu-
noblotting results) and cell-surface MHC I (Fig. 2B, FACS results)
in drug-naı ¨ve recipient cells, indicating that soluble factors such as
cytokines could be responsible for the MHC I induction.
Type I IFNs, including IFN-as and IFN-b, are known strong
regulators of MHC I expression [24,25] and could be involved in
TPT-induced MHC I expression. We measured the mRNA
expression of IFN-a1, IFN-a2 and IFN-b, as well as some other
cytokines in ZR-75-1 cells treated with TPT (40 nM for 1 hr
followed by 3-day incubation in drug-free medium) using real-time
Figure 1. TPT induces elevated expression of both total and cell-surface MHC I in breast cancer cells. (A) TPT induces elevated
expression of total cellular MHC I in breast cancer cells. Breast cancer cell lines ZR-75-1, T47D, MDA-MB-231 (MB-231) and MCF-7 were treated with
TPT (40, 200, 20, and 40 nM, respectively) for 4 days. Expression of total cellular MHC I was measured by immunoblotting using a polyclonal antibody
against MHC I. (B) The concentration effect of TPT on total cellular expression of MHC I. ZR-75-1 cells were treated with increasing concentrations of
topotecan (10 nM to 1 mM) for 4 days, followed by immunoblotting for total cellular MHC I expression. (C) Acute (1 hr) TPT exposure stimulates total
cellular expression of MHC I. ZR-75-1 cells were treated with TPT (40 nM) for increasing durations of time (0, 1, 6 and 24 hrs), followed by incubation
in drug-free medium for a total combined incubation of 4 days. Total cellular expression of MHC I was measured by immunoblotting. (D) TPT induces
elevated cell-surface expression of MHC I. ZR-75-1 cells were treated with 40 nM of TPT for 1 hr, followed by incubation in drug-free medium for 4
days. Cell-surface MHC I was measured by FACS analysis using the pan-MHC I monoclonal antibody, W6/32.
doi:10.1371/journal.pone.0032542.g001
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elevated by 13-fold (Fig. 2C). Other cytokines, such as IFN-a1,
IFN-a2, TNF-a, IL-1b, IL-4, IL-6, and IL-8, were also
significantly induced by TPT treatment (p,0.05). Furthermore,
secretion of IFN-b was confirmed and measured by an ELISA
assay. As shown in Table 1, treatment (24 hrs followed by 3-day
drug-free incubation) with TPT (40 nM) elevated IFN-b secretion
by 4.0 fold.
To verify the effect of IFN-b on MHC I expression, ZR-75-1
cells were treated with purified IFN-b (500 U/ml) and total
protein expression of MHC I was measured by immunoblotting.
As shown in Fig. 2D, purified IFN-b was shown to greatly increase
MHC I expression.
Activation of IFN-b signaling through the type I IFN
receptor (IFNAR) is responsible for TPT-induced MHC I
expression
To determine if IFN-b signaling is involved in the TPT-induced
MHC I expression, interferon (alpha, beta and omega) receptor
(subunit) 1 (IFNAR1) was silenced by IFNAR1-specific siRNA in
ZR-75-1 cells. As shown in Fig. 3A, IFNAR1 knockdown in ZR-
75-1 cells abolished the TPT-induced MHC I expression,
suggesting that autocrine/paracrine signaling through IFNAR
plays an important role in the MHC I induction by TPT. The
knockdown efficiency (about 80%) of IFNAR1 was determined by
immunoblotting (see Fig. 3A, right panel).
The role of secreted IFN-b in MHC I expression was also
assessed by using the neutralizing antibody against IFN-b in TPT-
treated ZR-75-1 cells. As shown in Fig. 3B, after 1 hr treatment
with TPT, ZR-75-1 cells were incubated in drug-free medium in
the presence of the neutralizing antibody against IFN-a or IFN-b
for 4 days. Only the neutralizing antibody against IFN-b, but not
IFN-a, blocked the TPT-induced cell-surface MHC I expression
(Fig. 3B, FACS analysis), suggesting that elevated secretion of IFN-
b from drug-treated cells is responsible for MHC I upregulation.
Also, the neutralizing antibody against IFN-b, but not IFN-a, was
shown to block ISG15 (an IFN-inducible gene) [26] induction in
TPT-treated ZR-75-1 cells (Fig. 3C), suggesting that IFN signaling
is primarily activated by IFN-b, but not IFN-a, in TPT-treated
ZR-75-1 cells. The anti-IFN-a antibody was shown to be
functional as it blocked IFN-a-induced expression of ISG15
(Fig. 3D).
Figure 2. Increased secretion of IFN-b is responsible for TPT-induced MHC I expression. (A) Conditioned media from TPT-treated cells
stimulate total cellular expression of MHC I in drug-naı ¨ve cells. ZR-75-1 cells were treated with 40 nM TPT for 1 hr, followed by incubation in drug-free
medium for 4 days. Drug-naı ¨ve ZR-75-1 cells were then replenished with the conditioned media for another 2-day incubation. The total expression of
cellular MHC I in recipient cells was measured by immunoblotting. (B) Conditioned media from TPT-treated cells stimulate cell-surface expression of
MHC I in drug-naı ¨ve recipient cells. Recipient ZR-75-1 cells were treated with the conditioned media as described above, and the cell-surface MHC I
expression was measured by FACS analysis. (C) TPT treatment increases mRNA levels of various cytokines in ZR-75-1 cells. Cells were treated with TPT
(40 nM) for 1 hr, followed by incubation in drug-free medium for 3 days. Total RNAs were harvested for analysis by real-time RT-PCR. The experiments
have been repeated twice. *: p-value,0.05. The error bar indicates standard deviation. (D) Purified IFN-b induces total cellular expression of MHC I.
ZR-75-1 cells were treated with recombinant human IFN-b (500 U/ml) for 2 days. The total expression of cellular MHC I in recipient cells was measured
by immunoblotting.
doi:10.1371/journal.pone.0032542.g002
Table 1. Cancer chemotherapeutics induce IFN-b secretion
(ELISA assay).







ZR-75-1 cells were treated with topotecan (40 nM), etoposide (1 mM), cisplatin
(6 mM), paclitaxel (3 mM), or vinblastine (6 nM) for 24 hrs, aspirated and washed,
followed by incubation in drug-free medium for 3 days. Levels of IFN-b protein
in the culture media were then measured by ELISA.
doi:10.1371/journal.pone.0032542.t001
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b autocrine signaling by TPT treatment is primarily responsible
for the TPT-induced MHC I expression.
TPT-induced MHC I expression requires active DNA
synthesis
The major cellular effects of CPTs including DNA damage
response and cell death have been attributed to the arrest of DNA
replication forks by drug-stabilized topoisomerase I-DNA covalent
adducts [27]. To test whether TPT-induced MHC I expression is
a downstream event of drug-induced replication fork arrest, cells
were treated with TPT in the presence of either the replication
inhibitor aphidicolin (APH) or the transcription inhibitor 5,6-
dichloro-1-b-D-ribobenzimidazole (DRB) for 30 min, followed by
further incubation in drug-free medium for 4 days. As shown in
Fig. 4A and 4B, the presence of APH, but not DRB, abolished
TPT-induced MHC I expression in ZR-75-1. Co-treatment of
TPT with APH in the donor cells was also shown to abolish the
conditioned media-induced MHC I expression in the drug-naı ¨ve
recipient cells (Fig. 4C). Furthermore, the effect of APH and DRB
on IFN-b mRNA expression in TPT-treated ZR-75-1 cells was
determined using real-time RT-PCR. As shown in Fig. 4D, APH,
but not DRB, significantly blocked the TPT-induced IFN-b
mRNA expression (p,0.05). Together, these results suggest that
IFN-b secretion and subsequent MHC I elevation in TPT-treated
cells require active DNA synthesis, implicating the formation of
Top1 cleavage complexes and their arrest of DNA replication
forks being responsible for these TPT effects.
TPT-induced MHC I expression depends on NF-kB
activation, but not caspase activation
NF-kB regulates expression of many cytokines, such as IFN-b,
TNF-a, IL-1b, IL-6 and IL-8, by activating their gene transcrip-
tion through direct binding to the promoters [28,29]. CPTs as well
as many cancer therapeutics are known to activate NF-kB [30–
33]. It has been demonstrated that NF-kB activation, like DNA
damage and cell death, is induced by CPTs in S-phase and is
dependent on the arrest of replication forks by CPT-induced
topoisomerase I-DNA covalent adducts [30,34]. To investigate
whether the TPT-induced expression of IFN-b and MHC I is due
to NF-kB activation, a NF-kB inhibitor, BAY 11-7085 [35], was
employed. As shown in Fig. 5A, BAY 11-7085 blocked the TPT-
induced MHC I expression in ZR-75-1 cells, suggesting a key role
of NF-kB in TPT-induced MHC I expression. Furthermore,
conditioned media from ZR-75-1 cells co-treated with BAY 11-
7085 and TPT were unable to induce MHC I expression when
transferred to the drug-naı ¨ve recipient cells, suggesting that NF-kB
activation in the drug-treated donor cells is responsible for MHC I
expression in the recipient cells (Fig. 5B). This result points to a
role of activated NF-kB in elevating IFN-b expression/secretion in
the donor cells, which is responsible for the induced MHC I
expression in the recipient cells. Indeed, BAY 11-7085 co-
treatment significantly abolished IFN-b mRNA induction as
measured by real-time RT-PCR (p,0.05) (Fig. 5C). As a control,
we demonstrated the levels of BAY 11-7085 used in this study
specifically blocks IkBa degradation induced by direct TNF-a
treatment in ZR-75-1 cells (Fig. 5D).
Figure 3. IFN-b signaling through type I IFN receptor is responsible for the TPT-induced MHC I expression. (A) IFNAR1 knockdown
abolishes TPT-induced total cellular MHC I expression. On the left panel, ZR-75-1 cells were mock-transfected, or transfected with control siRNA or
IFNAR1-specific siRNA. 48 hrs post-transfection, cells were treated with TPT (or 0.1% DMSO as control) for 1 hr, followed by incubation in drug-free
medium for 4 days. Lysates were analyzed by immunoblotting. On the right panel, ZR-75-1 cells were transfected with control or IFNAR1-specific
siRNA. 72 hrs post-transfection, cells were harvested and immunoblotted with an anti-IFNAR1 antibody. (B) Neutralizing antibody against IFN-b, but
not IFN-a, blocks the TPT-induced cell-surface MHC I expression. ZR-75-1 cells were treated with TPT (40 nM or 0.1% DMSO as control) for 1 hr,
followed by incubation in drug-free medium with or without neutralizing antibody against IFN-a (anti-a, 1.44610
3 NU/ml) or IFN-b (anti-b, 296 NU/
ml). Cell-surface MHC I expression was measured by FACS analysis. (C) Neutralizing antibody against IFN-b, but not IFN-a, blocks the TPT-induced
ISG15. Antibody and TPT treatments of ZR-75-1 cells were performed exactly the same as described in (B). Lysates were immunoblotted for ISG15
expression. (D) Neutralizing antibody against IFN-a inhibits IFN-a-induced ISG15 expression. ZR-75-1 cells were co-incubated with IFN-a (100 U/ml) in
the presence or absence of anti-IFN-a antibody (1.44610
3 NU/ml) for 2 days. Cells were then harvested and immunoblotted with an anti-ISG15
antibody.
doi:10.1371/journal.pone.0032542.g003
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catastrophe [36,37]. In Fig. 5E, we show that the general caspase
inhibitor Z-VAD-FMK did not block the TPT-induced MHC I
expression, suggesting that the MHC I induction is independent of
the apoptotic pathway. As a control, Z-VAD-FMK was shown to
block staurosporine-induced PARP-1 cleavage (Fig. 5F).
Taken together, these results suggest that the TPT-induced
IFN-b secretion and MHC I expression is dependent on NF-kB
activation, but independent of caspase activation.
Cancer chemotherapeutics and ionizing radiation induce
MHC I expression and IFN-b secretion
To test whether elevated MHC I expression through IFN-b
secretion/signaling is a general phenomenon induced by cancer
chemotherapeutics, ZR-75-1 cells were treated with etoposide (a
topoisomerase II inhibitor), cisplatin (a DNA damaging agent),
paclitaxel (a microtubule stabilizer) and vinblastine (a microtubule
destabilizer). As shown in Fig. 6A, all of these drugs, like TPT,
induced elevated expression of total cellular MHC I as evidenced
by immunoblotting. Furthermore, the cell-surface expression of
MHC I was also found to be greatly enhanced by these cancer
chemotherapeutics (Fig. 6B). Moreover, we measured the protein
levels of IFN-b in the media of drug-treated ZR-75-1 cells using
ELISA assay. As shown in Table 1, treatments (24 hrs followed by
3-day drug-free incubation) with etoposide (1 mM), cisplatin
(6 mM), paclitaxel (3 mM) and vinblastine (6 nM) elevated IFN-b
secretion by 3.5, 2.7, 2.7 and 2.8 folds, respectively. These results
suggest that tumor cell MHC I expression and IFN-b secretion
may be commonly induced by many different types of cancer
chemotherapeutic agents.
Since ionizing radiation, like TPT, is known to induce DNA
double-strand breaks and NF-kB activation, we investigated
whether ionizing radiation can similarly induce IFN-b expres-
sion/secretion and elevate MHC I expression. We showed that
conditioned media from irradiated ZR-75-1 cells, when trans-
ferred to unirradiated recipient cells, increased the expression of
both total cellular (Fig. 6C, immunoblotting results) and cell-
surface (Fig. 6D, FACS results) MHC I in the recipient cells,
suggesting that MHC I elevation in the recipient cells is due to
secreted soluble factors such as cytokines from the irradiated donor
cells. Indeed, when neutralizing antibody against IFN-b, but not
IFN-a, was added to the conditioned media from irradiated cells,
much reduced expression of MHC I was observed in the
unirradiated recipient cells (Fig. 6D). Collectively, these results
suggest that IFN-b-mediated MHC I expression may be
commonly induced by both cancer chemotherapeutics and
ionizing radiation.
Discussion
Our results demonstrate that the topoisomerase I-targeting
anticancer drug topotecan (TPT) induces elevated secretion of
multiple cytokines and increased MHC I expression in breast
cancer cells. Silencing of IFN-b by siRNA or addition of purified
IFN-b (see Fig. 2D) had a large effect on MHC class I expression,
suggesting a causal relationship between elevated IFN-b signaling
and increased MHC I expression in TPT-treated breast cancer
cells. By contrast, silencing of the TNF-a receptor by siRNA did
not affect MHC class I expression in TPT-treated ZR-75-1 cells,
and addition of purified TNF-a (or IL-6) to ZR-75-1 cells had no
observable effect on MHC I expression (slight increase in MHC
class I expression was observed only at a high concentration (i.e.
5 ng/ml) of TNF-a (Shan Wan and Leroy F. Liu; unpublished
results). Studies using the conditioned media from TPT-treated
tumor cells further support the notion that increased secretion of
IFN-b can elevate MHC I expression through autocrine/
paracrine signaling.
Our studies have also demonstrated that TPT-induced IFN-b
secretion and MHC I expression require active DNA synthesis
since co-treatment (1 hr, followed by further incubation in drug-
free medium for 4 days) with the replication inhibitor aphidicolin,
Figure 4. TPT-induced elevation of MHC I and IFN-b is DNA replication-, but not transcription-, dependent. (A) TPT-induced MHC I
expression require active DNA synthesis. ZR-75-1 cells were pre-treated with APH (10 mM) for 30 min, followed by 0.1% DMSO or TPT (40 nM)
treatment for 1 hr, and subsequent incubation in drug-free medium for 4 days. Expression of MHC I was then measured by immunoblotting. (B) TPT-
induced MHC I expression is independent of transcription. ZR-75-1 cells were pre-treated with the transcription inhibitor DRB (150 mM) for 30 min,
and then treated with TPT as described in (A). Expression of MHC I was measured by immunoblotting. (C) Conditioned medium-induced MHC I
expression in recipient cells requires active DNA synthesis in TPT-treated donor cells. Recipient ZR-75-1 cells were incubated with conditioned media
from TPT-treated donor cells as described in (A). The total expression of cellular MHC I in recipient cells was then measured by immunoblotting.
(D) TPT-induced IFN-b mRNA expression requires active DNA synthesis. ZR-75-1 cells were pretreated with APH (10 mM) or DRB (150 mM) for 30 min
prior to co-incubation with TPT (40 nM, 1 hr), followed by drug-free incubation for 3 days. Total RNAs were isolated for real-time RT-PCR analysis. The
experiments have been repeated three times. *: p-value,0.05. The error bar indicates standard deviation.
doi:10.1371/journal.pone.0032542.g004
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stimulatory effect. It has been well documented that tumor cell
killing by CPTs occurs specifically in S phase and requires active
DNA synthesis, as co-treatment with the replication inhibitors
protects tumor cells from CPT cytotoxicity [19]. In addition,
CPTs are known to activate NF-kB in S phase, which also requires
active DNA synthesis [30,34]. It has been proposed that CPT-
induced Top1-DNA covalent adducts arrest the advancing
replication forks, resulting in tumor cell death as well as DNA
damage responses including activation of NF-kB [16,30]. The
transcription factor NF-kB is a major stress sensor that responds to
various stimuli [28,38]. Activation of NF-kB has been shown to
induce diverse target genes at the transcription level, including
multiple cytokines such as TNF-a, IL-1b, IFN-b, IL-6, IL-8 and
others [28,29]. It is noteworthy that only the promoter of IFN-b,
but IFN-a, contains a NF-kB binding site [29]. Our inhibitor
studies have suggested that TPT-induced MHC I expression is
dependent on NF-kB activation. It seems likely that TPT-induced
MHC I expression is due to the activation of the NF-kB/IFN-b/
MHC I signaling axis. In this regard, it is interesting to point out
that many cancer chemotherapeutics (e.g. etoposide, cisplatin,
paclitaxel and vinblastine) and ionizing radiation are known to
activate NF-kB [31–33,39]. Consequently, elevated MHC I
expression induced by other cancer therapeutics as demonstrated
in our studies could also be due to the activation of the same NF-
kB/IFN-b/MHC I signaling axis.
Selective depletion of T regulatory cells by certain cancer
therapeutics has been proposed to be a key mechanism for
enhanced antitumor immune response [40]. However, increasing
evidence has also pointed to activation of type I IFN signaling as
another mechanism for chemotherapy-enhanced antitumor immu-
nity in mice [5,41–43]. For example, cyclophosphamide adminis-
tration has been shown to stimulate antigen-specific CTL response
in mice vaccinated with a peptide antigen [5]. However, in IFNAR
knockout mice, cyclophosphamide-induced stimulation of antigen-
specific T cells was diminished, suggesting a critical role of type I
IFN signaling in the immune-modulation by anticancer drugs [5].
Mostsignificantly,theefficacyofadoptiveimmunotherapyisgreatly
reduced in mice co-treated with anti-IFN-a/b antibody [43].
Proposedexplanationsfortheinvolvementoftype IIFNsignalingin
chemotherapy-induced antitumor immunity include augmentation
of memory T cells [41], increased tumor infiltrating T lymphocytes
[42], and enhanced clonal expansion of antigen-specific CTLs [5].
Our results suggest that elevated tumor cell antigen presentation
through MHC I may represent yet another mechanism for
chemotherapy-enhanced antitumor immunity through increased
Figure 5. TPT-induced MHC I expression requires NF-kB activation, but not apoptotic caspases. (A) The NF-kB inhibitor BAY 11-7085
(BAY) blocks TPT-induced MHC I expression. ZR-75-1 cells were pretreated with BAY (10 mM) for 30 min, followed by co-incubation with 0.1% DMSO
or TPT (40 nM) for 1 hr, and subsequent drug-free incubation for 4 days. Total cellular MHC I was then analyzed by immunoblotting. (B) The
conditioned medium-induced MHC I in recipient cells requires NF-kB activation in TPT-treated donor cells. Drug- naı ¨ve recipient ZR-75-1 cells were
incubated with the conditioned medium from TPT-treated donor cells as described in (A). Expression of total cellular MHC I in recipient cells was then
analyzed by immunoblotting. (C) TPT-induced IFN-b mRNA expression requires NF-kB activation. ZR-75-1 cells were pretreated with BAY (10 mM) for
30 min prior to co-incubation with TPT (40 nM, 1 hr), followed by drug-free incubation for 3 days. Total RNAs were isolated for real-time RT-PCR
analysis. The experiments have been repeated three times. *: p-value ,0.05. The error bar indicates standard deviation. (D) BAY specifically blocks
IkBa degradation induced by TNF-a treatment. ZR-75-1 cells were treated with TNF-a (10 ng/ml) for 10 min, in the presence or absence of BAY
(10 mM). Expression of IkBa was measured by immunoblotting. (E) TPT-induced MHC I expression is independent of caspase activation. ZR-75-1 cells
were pretreated with the pan-caspase inhibitor Z-VAD-FMK (Z-VAD, 10 mM) for 1 hr prior to co-incubation with TPT (40 nM, 1 hr), followed by
continued incubation in drug-free medium for 4 days. Cell lysates were then immunoblotted with the anti-MHC I antibody. (F) Staurosporine-induced
PAPR-1 cleavage requires caspase activation. ZR-75-1 cells were pretreated with Z-VAD-FMK (10 mM) for 1 hr followed by co-incubation with
staurosporine (STS, 0.5 mM) for 6 hrs. PARP-1 cleavage was then measured by immunoblotting.
doi:10.1371/journal.pone.0032542.g005
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observation is also relevant to the enhanced antitumor immune
response during metronomic chemotherapy (repeated low-dose
administration of anticancer drugs) [2].
Tumor irradiation has been reported to enhance the antitumor
efficacy of immunotherapy in mice [44,45]. However, the
molecular basis for the radio-immune sensitization remains
unclear. Our current studies have demonstrated that ionizing
radiation, like cancer chemotherapeutics, induces elevated expres-
sion of MHC I in an IFN-b-dependent manner in breast cancer
cells in vitro. It seems likely that ionizing radiation may also activate
the same NF-kB/IFN-b/MHC I signaling axis, resulting in
elevated tumor antigen presentation through MHC I and hence
increased tumor cell killing by CTLs, which could represent a
potential mechanism for radio-immune sensitization.
Our studies have demonstrated that many cytokines, in addition
to IFN-b, are induced by TPT-treated tumor cells in vitro. It seems
possible that elevated secretion of these cytokines by tumor cells, in
addition to stromal cells, may also contribute to the tumor
microenvironment in patients receiving chemo- or radio-therapy.
These cytokines could exert diverse effects on local and distal
tumor cells. For example, a ‘‘chemotherapy-induced bystander’’
phenomenon has been described [46]: conditioned media from
chloroethylnitrosourea (CENU)-treated tumor cells have been
shown to inhibit the growth of untreated tumor cells, suggesting
the presence of growth-inhibitory cytokines/secreted molecules in
the conditioned media. Further, metronomic administration of
various chemotherapeutic agents, such as cyclophosphamide,
methotrexate, paclitaxel, and vinblastine, has also been found to
inhibit angiogenesis, partially contributed by secreted TSP1 (as
reviewed in [47]). Additionally, the cytokine paracrine/autocine
signaling could contribute to the well-known radiation-induced
bystander effects, in which unirradiated tumor cells exhibit
biological effects of irradiation (e.g. cell death and DNA damage
response) due to signaling from nearby irradiated tumors [48].
Moreover, tumor irradiation has been shown to promote
angiogenesis, and local and distal metastasis (as reviewed in
[49]). Clearly, further studies are needed to better understand the
roles of tumor-secreted cytokines in immune modulation and
various bystander effects during chemo- or radio-therapy.
Materials and Methods
Cells and cell culture
Breast cancer cell lines ZR-75-1 and T47D were cultured in
complete RPMI, while MDA-MB-231 and MCF-7 in complete
DMEM. Both media (Sigma-Aldrich) were supplemented with
10% Fetalplex (Gemini Bio-Products), L-glutamine (2 mM),
penicillin (100 units/ml) and streptomycin (100 mg/ml). Cells
were maintained in a 37uC incubator with 5% CO2. All the cell
lines were obtained from American Type Culture Collection, and
were authenticated by the supplier.
Figure 6. Cancer chemotherapeutics and ionizing radiation induce MHC I expression in breast cancer cells. (A) Cancer
chemotherapeutics induce elevated expression of total cellular MHC I in breast cancer ZR-75-1 cells. Cells were treated with topotecan (40 nM),
etoposide (1 mM), cisplatin (6 mM), paclitaxel (3 mM), and vinblastine (6 nM) for 24 hrs, followed by incubation in drug-free medium for 3 days.
Expression of total cellular MHC I was measured by immunoblotting. (B) Cancer chemotherapeutics induce cell-surface expression of MHC I in ZR-75-
1 cells. ZR-75-1 cells were treated with different anticancer drugs as described in (A). Expression of cell-surface MHC I was then determined by FACS
analysis. (C) Conditioned media from c-irradiated cells induce elevated total cellular expression of MHC I in radiation-naı ¨ve recipient cells. Donor (ZR-
75-1) cells were irradiated with c-ray (2 Gy) for 3, 4, and 5 times. The conditioned media were then transferred to radiation-naı ¨ve recipient (ZR-75-1)
cells. After 48 hrs, cell lysates were harvested for immunoblotting analysis. (D) Induction of MHC I expression in drug naı ¨ve recipient cells depends on
IFN-b in the conditioned medium from irradiated donor cells. Radiation-naı ¨ve recipient (ZR-75-1) cells were incubated with the conditioned medium
from irradiated (2 Gy64) donor (ZR-75-1) cells in the presence of the neutralizing antibody against IFN-a (anti-a) or IFN-b (anti-b) for two days. Cell-
surface MHC I in the recipient (ZR-75-1) cells was then measured by FACS analysis.
doi:10.1371/journal.pone.0032542.g006
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Allanticancerdrugs(i.e.topotecan,etoposide,cisplatin,paclitaxel,
and vinblastine), the replication inhibitor aphidicolin and the
transcription inhibitor 5, 6-dichloro-1-b-D-ribobenzimidazole, and
apoptosis inducer staurosporine were purchased from Sigma-
Aldrich, and stored in DMSO (except for cisplatin which is stored
inwater containing 0.9% NaCl). The pan-caspase inhibitor Z-VAD-
FMK was purchased from Promega. The NF-kB inhibitor BAY 11-
7085 was purchased from BIOMOL International. Purified
recombinant proteins IFN-a and IFN-b, and neutralizing antibodies
against IFN-a and IFN-b, were from PBL InterferonSource.
Ionizing radiation
1.2610
7 breast cancer ZR-75-1 cells were seeded in 150 mm
culture dishes 24 hrs prior to irradiation. Cells (80–90% confluent)
were irradiated with 2 Gy gamma ray every 24 hrs for 3, 4 and 5
times, and were replenished with fresh media (15 ml) 1 hr after the
last irradiation. The (conditioned) media were then collected
24 hrs later. Collected (conditioned) media were passed through
0.45 mm syringe filters to remove dead cells and debris, followed
by storage in a 220uC freezer.
Immunoblotting
Immunoblotting was performed as described previously [50].
Briefly, cells were lysed with 66Laemmli SDS gel sample buffer,
followed by boiling for 10 min. Cellular proteins were fractionated
by SDS-PAGE, transferred to nitrocellulose membrane (What-
man), and probed with antibodies against MHC Class I (rabbit
polyclonal anti-MHC I heavy chain antibody; Santa Cruz), a-
tubulin (Developmental Studies Hybridoma Bank), IkB-a (Cell
Signaling), IFNAR1 (Abcam), PAPR (Cell signaling), or ISG15
(raised against human ISG15). Proteins were visualized using
SuperSignal West Pico Chemiluminescent Substrate (Pierce).
Secreted IFN- b Measurement
ZR-75-1 cells were treated with topotecan, etoposide, cisplatin,
paclitaxel, and vinblastine for 24 hrs, followed by incubation in
drug-free medium for 3 days. Levels of IFN-b protein in the
culture media were then measured using a VeriKine-HS
TM Human
Interferon-Beta Serum ELISA kit (PBL InterferonSource) accord-
ing to the manufacturer’s protocol.
Real-time RT-PCR
Total RNAs were isolated with Trizol reagent (Invitrogen) and
the RNeasy Mini Kit (Qiagen). About 1–2 mg of total RNAs were
used for the synthesis of first-strand cDNA using the SuperScript
III First-Strand Synthesis System (Invitrogen). Real-time RT-PCR
was performed in the 7900HT Fast Real-Time PCR System
(Applied Biosystems) with the use of SYBR Green PCR Master
Mix (Applied Biosystems). Results were analyzed with SDS 2.2
software using the
2DCT method [51]. The following primers were
used: b-actin-F (59- GGCACCCAGCACAATGAAGATCAA-39)
and b-actin-R (59- ACTCGTCATACTCCTGCTTGCTGA-39);
IFN-a1-F (59- AGGAGGAGTTTGATGGCAACCAGT-39) and
IFN-a1-R (59- TGCTGGTAGAGTTCGGTGCAGAAT-3); IFN-
a2-F (59- AAGGACTCATCTGCTGCTTGGGAT-39) and IFN-
a2-R (59- TCACACAGGCTTCCAGGTCATTCA-39); IFN-b-F
(59- TGTGGCAATTGAATGGGAGGCTTG-39) and IFN-b-R
(59- TCTCATAGATGGTCAATGCGGCGT-39); IFN-c-F (59-
TGCAGGTCATTCAGATGTAGCGGA-39) and IFN-c-R (59-
TGTCTTCCTTGATGGTCTCCACACTC-39); IL-1b-F (59-T -
CTGTACCTGTCCTGCGTGTTGAA-39) and IL-1b-R (59-T -
GCTTGAGAGGTGCTGATGTACCA-39); IL-2-F (59- ATCC-
CAAACTCACCAGGATGCTCA-39) and IL-2-R (59- GCAC-
TTCCTCCAGAGGTTTGAGTTCT-39); IL-4-F (59- TACAG-
CCACCATGAGAAGGACACT-39) and IL-4-R (59- ACGTA-
CTCTGGTTGGCTTCCTTCA-39); IL-6-F (59- TCAATGAG-
GAGACTTGCCTGGTGA-39) and IL-6-R (59- TACTCATC-
TGCACAGCTCTGGCTT-39); IL-10-F (59- AAGCTGAGAAC-
CAAGACCCAGACA-39) and IL-10-R (59- AAAGGCATTCTT-
CACCTGCTCCAC-39); IL-12-F (59- TGCAGGCCCTGAA-
TTTCAACAGTG-39) and IL-12-R (59- GTCACTGCCC-
GAATTCTGAAAGCA-39); TNF-a-F (59- AAGCCCTGGTAT-
GAGCCCATCTAT-39) and TNF-a-R (59- ATGATCCCAAAG-
TAGACCTGCCCA-39).
siRNA knockdown
Cells were transfected with control siRNA(SIC001, Sigma-
Aldrich) or IFNAR1 siRNA(s783, Ambion) with Oligofectamine
transfection reagent (Invitrogen), as described previously [50].
FACS analysis
Expression of cell-surface MHC I was measured using pan-
MHC Class I reactive monoclonal antibody W6/32 (Abcam) and
Cy2-conjugated goat anti-mouse IgG secondary antibody (Jackson
Immunoresearch Laboratories). Briefly, cells were trypsinized,
washed with ice-cold PBS containing 1% sodium azide (Sigma-
Aldrich), and incubated with primary antibody for 30 min on ice,
followed by 30 min incubation with the secondary antibody. After
washing, cells were analyzed by a flow cytometer (Beckman
Coulter FC500 Analyzer).
Supporting Information
Table S1 TPT treatment increases expression levels of cytokine
mRNAs in ZR-75-1 cells. ZR-75-1 cells were treated with TPT
(40 nM) for 1 hr, followed by incubation in drug-free medium for
3 days. Total RNAs were isolated for real-time RT-PCR analysis.
Ct values for each gene are recorded in the table, and 2DDCt was
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